Cybin Inc. CYBN has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive...
Mark Velleca → David M. Epstein is out as CEO of cancer player Black Diamond Therapeutics, which is putting chairman Mark Velleca in charge. This is...
A Comprehensive Timeline Of COVID-19 Vaccines And Myocarditis Authored by Zachary Stieber via The Epoch Times (emphasis ours), 2020 Sept....
Pfizer-Funded Study Shows Poor Effectiveness For COVID-19 Vaccine In Young Children Authored by Zachary Stieber via The Epoch Times (emphasis...
According to EY, the professional services firm originally known as Ernst & Young, biopharma M&A deals during the first six months of 2023 more...
Travere Therapeutics’ kidney disease drug narrowly failed its confirmatory study seven months after it won accelerated approval. Travere said Thursday...
Every year, without fail, the Endpoints 11 proves to be the most challenging project I face — and definitely remains the most fun. In an industry...
On Wednesday, the Senate introduced a revamped cannabis banking bill featuring an updated title and several fresh provisions pertaining to federal financial...
After being rejected twice by the FDA in the past six years, Intarcia Therapeutics’ drug-device product to treat type 2 diabetes will be the subject...
Taysha Gene Therapies discontinued development of a neurodegenerative therapy after the FDA again insisted on a potentially impossible study, the company...
When annually proclaiming which startups are poised to become the next big thing in biotech, you ought to track their progress every so often. In the...
ARS Pharmaceuticals revealed late Tuesday evening that the FDA rejected what would have been the first epinephrine nasal spray. The FDA requested another...
Red State Pharmacists Use 'Religious' Loophole To Deny Patients Ivermectin: Doctor Authored by Matthew Lysiak via The Epoch Times (emphasis...
FDA Has 'Gone Rogue' In Its Approval Of New COVID-19 Boosters: Dr. Robert Malone Authored byh Tom Ozimek and Joshua Philipp via The Epoch...
Elutia Inc (NASDAQ: ELUT) shares bolstered a whopping 33% today as the company recently shared that they’ve secured about $10.5 million in funding through...
PLAINVILLE, Mass. — Just a year after opening its $180 million viral vector manufacturing site in Massachusetts, Thermo Fisher already has expansion...
The Appeal of Penny Stocks: Are Inexpensive Shares Under $1 a Good… The post 3 Penny Stocks To Buy For Under $1, Are They Worth The...
Clinical-stage biopharma company Reunion Neuroscience has received the FDA’s clearance on its Investigational New Drug (IND) application to begin a Phase...
COVID-19 Vaccines Revealed To Be 'Neither Safe, Nor Effective': Watchdog Authored by Naveen Athrappully via The Epoch Times (emphasis ours), COVID-19...
We took a close look at Nascent Biotech Inc. (OTCMKTS:NBIO) two weeks ago on September 6 (that piece is here) as a classic deep value […]...
Arialys is developing an antibody therapeutic, ART5803, to treat anti-NMDA receptor encephalitis (ANRE), one of the most common forms of autoimmune encephalitis....
Penny stocks to watch this week. The post 3 Hot Penny Stocks To Watch Before The September Fed Meeting appeared first on Penny Stocks to Buy,...
TARRYTOWN, NY — For over three decades, Regeneron has been synonymous with one thing in the drug industry: antibodies. Blockbusters like Dupixent, Eylea,...
Building on its infectious disease work in Covid-19, malaria and tuberculosis, BioNTech is now rolling out a Phase I/II test of a jab to protect against...
The Multidisciplinary Association for Psychedelic Studies (MAPS) and its private subsidiary company, MAPS PBC shared the publication of the results...
FDA Refuses To Change Anti-Ivermectin Statements After Court Ruling Authored by Zachary Stieber via The Epoch Times (emphasis ours), Anti-ivermectin...
Jonathan Milner, who owns 6.14% of Abcam stock, said he will request that Abcam’s Board of Directors instead hold a General Meeting (EGM) to consider...
New research has shed light on why immune checkpoint blockade immunotherapy does not always work in some cancers with a high tumor mutational burden. The...
The FDA approved a new JAK inhibitor, momelotinib, from GSK for adults with the rare bone marrow cancer myelofibrosis who also have anemia. The approval...
A Seattle-area tech company has reason to smile after receiving clearance from the Food and Drug Administration for its tooth-tapping device and machine...